Related Experiment Video
Updated: Jun 15, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Liver fibrosis in overweight patients
V Ratziu1, P Giral, F Charlotte
1Service d'Hépatogastroenterologie, Hôpital Pitié Salpétrière, Paris, France.
Gastroenterology
|June 2, 2000
Summary
Overweight patients with abnormal liver function tests frequently have liver fibrosis. A simple clinicobiological score can help identify those who may benefit from a liver biopsy.
Area of Science:
- Hepatology
- Internal Medicine
- Clinical Pathology
Background:
- Overweight individuals with abnormal liver function tests present a diagnostic challenge regarding the need for liver biopsy.
- The prevalence and risk factors for serious liver injury in this population are not well-established.
Purpose of the Study:
- To determine the frequency of septal fibrosis and cirrhosis in overweight patients with abnormal liver function tests.
- To identify clinical, biological, and histological factors associated with liver fibrosis in this cohort.
- To develop a predictive score for identifying patients who require liver biopsy.
Main Methods:
- Retrospective study of 93 overweight patients (BMI > 25 kg/m²) with abnormal liver function tests and no other known liver disease.
- Analysis of clinical, biological (including triglycerides and ALT), and histological variables.
- Statistical testing for association with septal fibrosis or cirrhosis.
Main Results:
- Septal fibrosis was found in 30% of patients, with 11% having cirrhosis.
- Independent risk factors for septal fibrosis included age (≥50 years), higher BMI (≥28 kg/m²), elevated triglycerides (≥1.7 mmol/L), and elevated ALT (≥2N).
- A predictive score combining age, BMI, triglycerides, and ALT demonstrated high sensitivity (100%) for ruling out septal fibrosis.
Conclusions:
- Septal fibrosis is common in overweight patients with abnormal liver function tests.
- A clinicobiological score incorporating age, BMI, ALT, and triglycerides can aid in selecting patients for liver biopsy.
- This score offers a valuable tool to improve the diagnostic pathway for non-alcoholic fatty liver disease in at-risk individuals.
Related Concept Videos
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...